Shopping Cart
- Remove All
Your shopping cart is currently empty
Piritrexim
🥰Excellent
Catalog No. T24644Cas No. 72732-56-0
Alias BW 301U
Piritrexim (BW 301U) is an orally available fat-soluble dihydrofolate reductase inhibitor with pulmonary toxicity used in the study of uroepithelial carcinoma and metastatic breast cancer.
Piritrexim
🥰Excellent
Purity: 99.68%
Catalog No. T24644Alias BW 301UCas No. 72732-56-0
Piritrexim (BW 301U) is an orally available fat-soluble dihydrofolate reductase inhibitor with pulmonary toxicity used in the study of uroepithelial carcinoma and metastatic breast cancer.
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $350 | In Stock | |
| 5 mg | $970 | In Stock | |
| 25 mg | $1,590 | In Stock | |
| 50 mg | $1,980 | In Stock |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "Piritrexim"
Gentamicin sulfate
Cited
SCH9724, NSC-82261, Gentamycin sulfate
T13261405-41-0
Gentamicin sulfate (SCH9724) is a wide-spectrum, aminoglycoside antibiotic used to inhibit protein synthesis in sensitive organisms.
- $31
Size
QTY
CitedTrimethoprim
NSC-106568, NIH 204, BW 56-72
T1153738-70-5
Trimethoprim (NSC-106568) is a Dihydrofolate Reductase Inhibitor Antibacterial. The mechanism of action of trimethoprim is as a Dihydrofolate Reductase Inhibitor, and Cytochrome P450 2C8 Inhibitor, and Organic Cation Transporter 2 Inhibitor.
- $45
Size
QTY
Pemetrexed
Pemetrexed acid, LY231514 Disodium Hydrate, LY231514
T0189137281-23-3
Pemetrexed (LY-231514 Disodium Hydrate), a guanine-derived antineoplastic agent, binds to and inhibits the enzyme thymidylate synthase (TS).
- $33
Size
QTY
Urea
Ureophil, E-Cardamoni, Carbonyldiamide, Carbamide
T073857-13-6
Urea (Carbonyldiamide) is formed in the liver from ammonia produced by the deamination of amino acids. It is the principal end metabolite of protein catabolism and accounts for about one-half of the total urinary solids.
- $30
Size
QTY
Sulfameter
Sulfametoxydiazine, 5-Methoxysulfadiazine
T0748651-06-9
Sulfameter (Sulfametoxydiazine) is a long-acting sulfonamide antibacterial agent used to treat urinary tract infections and leprosy.
- $31
Size
QTY
Pemetrexed disodium
LY231514 disodium
T0189L150399-23-8
Pemetrexed disodium (LY-231514) is a parenterally administered folate antagonist and antineoplastic agent, used in the treatment of non-small cell lung cancer and malignant mesothelioma. Pemetrexed disodium therapy has been associated with moderate rates of serum enzyme elevations during therapy, but has not been convincingly linked to instances of acute, clinically apparent liver injury.
- $37
Size
QTY
Diaveridine
EGIS-5645, CCRIS-3784, AI3-23935
T22045355-16-8
Diaveridine (AI3-23935) (DVD) is a popular antibacterial synergist that is widely used in combination with sulfonamide. It has been reported to be genotoxic to mammalian cells, but more studies are required to clarify this.
- $42
Size
QTY
Pyrimethamine
RP 4753, Pirimetamin, Pirimecidan
T084958-14-0
Pyrimethamine (Pirimecidan) is a competitive inhibitor of dihydrofolate reductase (DHFR), used as an antimalarial drug.
- $38
Size
QTY
Methotrexate Diglutamate
NSC-269401, NSC269401, NSC 269401
T2588641600-13-9In house
Methotrexate Diglutamate Small molecule compound present in the liver that acts as a partially purified human dihydrofolate reductase inhibitor.
- $1,630
Size
QTY
Pemetrexed disodium hemipenta hydrate Cited
Pemetrexed sodium hydrate, Pemetrexed Disodium Hydrate, LY-231514 Disodium Hydrate
T6226357166-30-4
Pemetrexed disodium hemipenta hydrate (LY-231514 Disodium Hydrate) is a new-type antifolate and antimetabolite for TS, DHFR, and GARFT. The Ki of Pemetrexed Disodium Hydrate for TS, DHFR and GARFT is 1.3 nM, 7.2 nM and 65 nM, respectively.
- $33
Size
QTY
Cited
Select Batch
Purity:99.68%
Contact us for more batch information
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.Product Introduction
Bioactivity
Chemical Properties
| Description | Piritrexim (BW 301U) is an orally available fat-soluble dihydrofolate reductase inhibitor with pulmonary toxicity used in the study of uroepithelial carcinoma and metastatic breast cancer. |
| Targets&IC50 | Walker 256 cells:0.008 uM(ED50) |
| In vitro | Piritrexim (0.1 to 1.0 microM) was able to inhibit the replication of T.gondii in a mouse peritoneal macrophage model. The addition of sulfadiazine, which alone was ineffective, to piritrexim allowed inhibition of T.gondii replication at lower concentrations of piritrexim than when piritrexim was used alone.[5] |
| In vivo | Piritrexim (25-mg/m2/dose; oral) occurred the myelosuppression and mucositis in 4 of 4 patients but in none of the patients treated at the 15- and 20-mg/m2/dose levels.[6] Piritrexim (20 mg/m2/dose; oral) was rapidly absorbed, with the median time to peak level occurring 1.5 h after an oral dose, and the area under the concentration-time curve (AUC) was linearly related to the dose administered. Trough plasma piritrexim concentration strongly correlated with DLT (P = 0.0016). A trough plasma piritrexim concentration greater than 0.5 microM appeared to be predictive of toxicity. Eleven of 15 patients with trough concentrations exceeding this threshold experienced DLTs.[6] |
| Alias | BW 301U |
| Molecular Weight | 325.37 |
| Formula | C17H19N5O2 |
| Cas No. | 72732-56-0 |
| Smiles | CC=1C2=C(N=CC1CC3=C(OC)C=CC(OC)=C3)N=C(N)N=C2N |
| Relative Density. | 1.294g/cm3 |
Storage & Solubility Information
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Keywords
Preview
Related Tags: buy Piritrexim | purchase Piritrexim | Piritrexim cost | order Piritrexim | Piritrexim chemical structure | Piritrexim in vivo | Piritrexim in vitro | Piritrexim formula | Piritrexim molecular weight
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.